# Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Source: https://onco.cc/trials/nct06680752/  
OnCo record `nct06680752` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cyclophosphamide and Fludarabine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by ARCE Therapeutics, Inc., now recruiting.

## Summary

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS is a phase 1/2 interventional study registered as NCT06680752 by ARCE Therapeutics, Inc., with 49 participants planned, started 2025-05-20 and due to reach its primary completion in 2028-10. Interventions recorded: ARD103, Cyclophosphamide and Fludarabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06680752
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multicenter Trial to Assess the Safety and Efficacy of ARD103 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Sponsor: ARCE Therapeutics, Inc.
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT06680752: https://clinicaltrials.gov/study/NCT06680752

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [ARD103](https://onco.cc/drugs/ard103/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06680752.json